Skip to content
Search

Latest Stories

REALITY CHECK: The uneven playing field of hub and spoke

Louise Laban argues that the government’s latest impact assessment into the ‘hub and spoke’ model of dispensing suggests the cost of a hub is beyond all but the largest of pharmacies…

The second long-awaited consultation on proposed changes to UK legislation to allow all community pharmacies to access hub and spoke dispensing is underway.


Six years on from the original consultation, there remains speculation within the pharmacy market that the proposals may allow larger chains with automated hubs to charge smaller chains and independent pharmacies for “prescription assembly services” leading to an erosion of profits that cannot be recouped by any amount of patient facing services.

Unfortunately the impact assessment into hub and spoke published by the Department of Health and Social Care (DHSC), alongside the new consultation, does little to dispel this myth and suggests the cost of a hub is beyond all but the largest of pharmacies.

This in fact could not be further from the truth and had the impact assessment looked at hub and spoke models being used today by pharmacies other than what appears to be the big players they would have come to a very different conclusion.

By its own admittance the impact assessment has focussed on the large scale hubs that have been in operation for some time as well as responses and figures from the original 2016 consultation. But time and technology move on and the reality today is very different from the picture painted in the DHSC assessment.

The DHSC impact assessment claims it is only aware of six pharmacy businesses out of 3,000 across the whole sector who are using automation. We know this number is far higher and the six referred to appear to be the larger groups who have established large central hubs using multi-million pound technology.

The figure does not include other hub solutions currently available and in operation across the market today. There are early adopters out there who are already demonstrating that hub and spoke dispensing technology is an option for pharmacies of all sizes, including smaller groups with as few as three branches.

Perhaps most concerning are the figures and formulas used as a baseline throughout the assessment. We’re told in the assessment pharmacy businesses processing less than 250,000 items per week, 12m per year, may lack the scale to invest in their own hub and could instead benefit from proposals to outsource hub operations.

Such a statement shows that only one hub solution was considered as part of the assessment and it is not an accurate reflection of the market we know today. There are hubs already established that process far fewer items than 250,000 per week.

There are pharmacies who have installed automation for significantly lower volumes and who are now seeing efficiencies in terms of costs, increased staff satisfaction and the ability to provide revenue generating services without increasing staffing levels.

There are scalable solutions on the market that are available and already in use. There are, of course, lots of factors to consider, but we think a starting point for hub and spoke requires a capital investment of under £100,000 for a group of three plus pharmacies with a combined total of 45,000 items of month. Space will always be a consideration too of course but you could start your hub and spoke journey with around 10 square metres of space.

Technology can then be scaled up for larger groups. So for a group of say 18 pharmacies doing 120,000 items per month you’d be looking at a capital investment of under £500,000. This investment would provide capacity to do double the volume in a single shift. This would obviously require additional space and you would be looking at around 40 square metres as your starting point.

The assessment rightly points out that as hub pharmacies are likely to have a higher volume of dispensing, they may be able to negotiate better purchasing terms. However, it goes on to say that even where hub pharmacies do secure a better price due to their size, there is no guarantee savings will be passed on to the spoke pharmacies, and indeed, it may be the case that they could charge a slightly higher price as a way of recouping the service costs of the hub.

This is exactly why it could be advantageous to establish your own hub as a smaller group of pharmacies or independents. Outsourcing and using fewer, larger scale hubs will result in charges for independent and smaller multiple pharmacies and there is the potential that the benefits of volume buying will not be passed on to spoke pharmacies.

The more hubs the healthier the market. As the assessment says, under new legislation, hub and spoke dispensing may be possible between two or more pharmacies on a local level without any automation, with assembly or part dispensing carried out manually. I’d go one step further and suggest hub and spoke dispensing would be possible between a few higher volume pharmacies with the option to automate.

Statements that only 40 per cent of items can go through a pharmacy hub and set up costs for spoke pharmacies will cost £4,000 once again appear to have been based on large scale automated hub technology.

Affordable and scalable technology designed specifically for smaller independent pharmacies or groups of pharmacies have not been taken into account.

These smaller solutions can and do already process 70 per cent of items through the hub.

There are also hub solutions for spoke pharmacies available that cost hundreds of pounds, not thousands. In addition, cost estimates quoted in the DHSC impact assessment, that technology for dispensing hubs costs in the order of £1-2 million are not based on the technology that is available now. Hub dispensing technology is readily available for less than £100,000.

The impact assessment makes some great observations around improving patient safety and freeing up time for clinical services. However, I find it concerning the assessment has only considered the large scale hub and spoke model which requires significant investment.

Louise Laban is sales and marketing director at Centred Solutions.

More For You

How to leverage data to drive pharmacy growth

Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy.

Pharmacy challenges: How data can help spot the ‘elephant in the room’

Adopting new technologies is vital for moving pharmacy forward — but are you fully harnessing the data these tools generate?

“Being able to utilise, manage, and interpret the data these technologies provide can help add more value to your business,” said Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy, while speaking at the recent Pharmacy Business Conference.

Keep ReadingShow less
Branded OTC products can boost pharmacy revenue and promote self-care, says PAGB CEO

Michelle Riddalls

How branded OTC products can help struggling community pharmacies - PAGB chief explains

Branded over-the-counter (OTC) products could play a vital role in promoting self-care and supporting the sustainability of community pharmacies, said Michelle Riddalls, CEO of PAGB – the consumer healthcare association – during the recent Pharmacy Business Conference.

Riddalls emphasised that OTC medicines not only enable consumers to better manage their health through self-care but also offer pharmacies an opportunity to increase revenue, particularly during a time of mounting financial pressure.

Keep ReadingShow less
How Peptides Are Transforming Modern Drug Development

Modern Drug Development

How Peptides Are Transforming Modern Drug Development

The pharmaceutical industry is rapidly evolving, embracing new technologies and methodologies. Peptides are emerging as a crucial component in this transformation, offering innovative solutions to drug development. This shift is not only reshaping how drugs are discovered but also enhancing their efficacy and safety.

In recent years, the pharmaceutical landscape has undergone significant changes, driven by advancements in technology and scientific understanding. One of the most promising areas of innovation is the use of peptides in drug development. These short chains of amino acids have proven to be versatile tools, capable of targeting specific cells or molecules with high precision. In this context, certain bpc 157 peptide research peptides have been highlighted for their potential applications in various therapeutic areas, showcasing the promise that peptides hold for modern pharmaceutical studies.

Keep ReadingShow less
Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
Support for generic medicines manufacturers key to affordable healthcare- Teva UK director

Teva UK sounds alarm on accelerating consolidation of critical generic medicines

Photo credit: gettyimages

Exclusive: Teva UK calls for inclusion of generic manufacturers in policy talks

A healthy and vibrant generics marketplace supports not only patients but also contributes billions of pounds in savings to the drugs bill. However, growing pressures on generic medicine manufacturers could threaten this vital part of the healthcare ecosystem, warns Ryan Ruscoe, senior director of generics and OTC at Teva UK.

Speaking exclusively to Pharmacy Business, Ruscoe stressed the urgent need to address supply chain vulnerabilities, particularly for critical generic medicines.

Keep ReadingShow less